The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global research antibodies market is expected to exhibit a CAGR of 7.08% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Antibodies are glycoproteins and act as essential components of the immune system found in body fluids. They circulate in the blood and protect against antigens or foreign substances like bacteria and viruses. They are used as fundamental detection tools for biological research due to their specific recognition and affinity for antigens. Consequently, they play a crucial role in recognizing specific cellular components and the development of routine diagnostic medical tests in the research field. Some of the common technologies that are extensively used for antibody research include immunohistochemistry (IHC), Immunofluorescence, western blot, flow cytometry, Immunoprecipitation and enzyme-linked immunosorbent assay (ELISA).
Antibodies are vital tools used in laboratory techniques to identify target molecules. Therefore, a substantial rise in the prevalence of cancer represents one of the key factors influencing the demand for research antibodies to detect key cancer targets and use them in various applications. Apart from this, as stem cells help maintain and repair the tissues, they find applications in the developmental of biology, disease modeling research, drug development screening and cell therapy studies. This is further propelling the demand for high-quality antibodies for the characterization of various stem cells. Moreover, the global spread of the coronavirus disease (COVID-19) has increased the need for quick, potential treatments to halt viral transmission. This is promoting the adoption of research antibodies to gain insight into the immune system response for viral infection and prepare a viable vaccine. Furthermore, the rising investment in the research and development (R&D) activities to develop innovative research antibodies is anticipated to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global research antibodies market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, technology, source, application and end user.
Breakup by Type:
Breakup by Technology:
Breakup by Source:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam Plc, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Cell Signalling Technology Inc., F. Hoffmann La Roche Ltd., Lonza Group AG, Merck KGaA, PerkinElmer Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Technology, Source, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abcam Plc, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Cell Signalling Technology Inc., F. Hoffmann La Roche Ltd., Lonza Group AG, Merck KGaA, PerkinElmer Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at